Investors

Sensei is a clinical-stage immunotherapy company committed to the discovery and development of next-generation therapies for the treatment of cancer. The company is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases.  It has developed two unique approaches. The first approach is Sensei’s proprietary ImmunoPhage™ platform, which leverages the self-adjuvanted and highly immunogenic properties of engineered bacteriophage. This platform allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. The second approach is the company’s monoclonal antibody and nanobody platform, which is comprised of unique human monoclonal antibodies and alpaca-derived nanobodies that are selectively active only in the tumor microenvironment.

Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach.

Sensei’s ImmunoPhage pipeline includes its most advanced product candidate, SNS-301, which is currently being evaluated in combination with the PD-1 inhibitor, pembrolizumab, for the treatment of squamous cell carcinoma of the head and neck.

Additional ImmunoPhage programs include SNS-401, a preclinical candidate for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.